Applications of TransFix: Stabilisation of Adipose-derived Stromal Vascular Fraction (SVF)
Independent research involving the use of TransFix to stabilise Adipose derived Stromal Vascular Fraction (SVF) for flow cytometry has been published.
Stromal vascular fraction (SVF) from adipose tissue contains a mixed population of cells including erythrocytes, leukocytes, endothelial cells and a high concentration of MSCs. It is thought that SVF could be administered immediately for the treatment of a range of conditions (as opposed to after MSC expansion in culture), allowing for the treatment to be delivered on the same day that the adipose tissue was collected and prepared (Karsten et al, case study 1).
Benefits of TransFix
TransFix has been shown to stabilise the mixed cell population in Adipose-derived Stromal Vascular Fraction. This can assist any delays caused by analysing batches of SVF samples in a multi center setting, when samples are required to be stored and shipped.
Please note that Cytomark have not validated the use of TransFix for SVF for IVD use.
Case Study 1: Evaluation of TransFix® Mediated Stabilisation of Adipose-Derived Stromal Vascular Fraction for Delayed Flow Cytometry Analysis
In multi-centre studies where stromal vascular fraction (SVF) is used for immediate treatment, post-hoc assessment at a central or core facility of cell numbers, cell viability and immunophenotype may be necessary. Additional time taken to ship and store these samples can lead to time-dependant loss of cell markers and a reduction in cell viability. This paper provides an assessment of the suitability of TransFix for the purpose of SVF stabilisation across 77 consenting patients. The data shows that following treatment with TransFix the samples remain stable for up to seven days providing accurate total nucleated cell counts, stable populations of CD90, CD31 and CD45 markers and the potential to back calculate cell viability in the original sample. The authors also report an apparent increase in cell numbers post-stabilisation that is hypothesised to be due to a reduction in cell clumping as a result of treatment with TransFix.
Reference: E. Karsten, J. Sung, C. Morgan, B. Herbert, G. Vesey (2014) Evaluation of TransFix® Mediated Stabilisation of Adipose-Derived Stromal Vascular Fraction for Delayed Flow
Cytometry Analysis. Open Journal of Regenerative Medicine 3; 54-63. DOI: 10.4236/ojrm.2014.33007
TransFix is available in 1ml or 20ml vials, or in TransFix Sample Storage Tubes which contain 0.2ml TransFix for the addition of 1ml of sample. If you have any questions regarding the use of TransFix for Bronchoalveolar lavage fluid (BALF), please contact us.